IngateyGen’s Solution is to remove the allergens from the source and produce a peanut substantially equivalent to conventional peanut in nutrition and yield in the field. We have established a two-phase commercialization strategy:
During Phase 1: We used RNAi technology to produce a GMO peanut reduced in allergen content.
During Phase 2: We are now using CRISPR to produce a Non-GMO Allergen-Free-Peanut.
IngateyGen performed a pilot study using RNAi technology and performed 3 years of field trials. Analysis by an independent lab show the following success:
Major allergens Ara h 1 and Ara h 2 were significantly reduced and/or eliminated.